Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00600951 · ClinicalTrials.gov registry record
Evaluation of the Risk of NSF Following MultiHance Injection in Patients With Chronic Kidney Disease
A clinical trial of Renal Insufficiency, sponsored by Bracco Diagnostics.
- Completed
- Registry status
- 366
- Enrollment target
- 1
- Study location
NCT00600951: Completed study of Renal Insufficiency, sponsored by Bracco Diagnostics.
NCT00600951 is a study of Renal Insufficiency that has completed, run by Bracco Diagnostics. The registered enrollment target is 366 participants, above the 85-participant average among 22 other Renal Insufficiency trials with a reported enrollment target (331% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00600951, a study of Renal Insufficiency, has completed, sponsored by Bracco Diagnostics.
- COMPLETED
- Registry status
- 366 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this long-term study is to prospectively compare the incidence of NSF in two cohorts (Cohort 1 - patients with moderate chronic kidney disease eGFR 30 to 59 and Cohort 2 - patients with severe chronic kidney disease or kidney failure eGFR \<30).
Conditions Studied
Study Locations (1)
New Jersey
- Bracco Diagnostics Inc. - Princeton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 366 participants |
| Start Date | 2008-01 |
| Est. Completion | 2013-08 |
What the finished NCT00600951 record still lists
NCT00600951 is an observational study that tracks outcomes without assigning an intervention. The registered 366 participants enrollment target is mid-sized for trials with a published cap, above the 85-participant average among 22 other Renal Insufficiency trials with a reported enrollment target (331% higher).
The record links to 1 condition, with Renal Insufficiency appearing as the primary indexed condition, and to 0 interventions.
NCT00600951 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT00600951 about?
NCT00600951 is a clinical study titled "Evaluation of the Risk of NSF Following MultiHance Injection in Patients With Chronic Kidney Disease". The objective of this long-term study is to prospectively compare the incidence of NSF in two cohorts (Cohort 1 - patients with moderate chronic kidney disease eGFR 30 to 59 and Cohort 2 - patients with severe chronic kidney disease or kidney failure eGFR \<30).
What is the current status of trial NCT00600951?
This trial is currently completed. The enrollment target is 366 participants. The study started on 2008-01. Estimated completion is 2013-08.
What conditions does trial NCT00600951 study?
This clinical trial studies the following conditions: Renal Insufficiency.
Who is sponsoring clinical trial NCT00600951?
This trial is sponsored by Bracco Diagnostics, which has 37 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00600951 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Insufficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00600951's enrollment target sits among peer trials
366 3rd of 22 higher than 20 of 22 other Renal Insufficiency trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Renal Insufficiency trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study
RECRUITING · NA
-
A Study of LY3537982 in Participants With Kidney Problems Compared With Participants With Normal Kidney Function
RECRUITING · Phase 1
-
A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function
RECRUITING · Phase 1
-
A Study of Pharmacokinetics and Safety of LY3537031 in Participants With Normal Renal Function and Participants With Renal Impairment
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Assess the Pharmacokinetics of CC-122 in Subjects With Mild, Moderate, and Severe Renal Impairment
COMPLETED · Phase 1
-
"Pharmacokinetic Study of Fondaparinux in Inpatients With Renal Dysfunction"
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05083481 · 366 participants · Phase 1
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
- NCT05429632 · 366 participants · Phase 3
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
- NCT06979453 · 366 participants · Phase 3
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
- NCT04049604 · 365 participants · NA
IDENTIFY Study: Natural History of Maternal Neoplasia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia